Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 13/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | BCR | P11274 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.34 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.32 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13007159 | 0.99 | PDE9A (0.35) | PDE9AABL1BCRSLC2A1SLC2A2 | |
| SCHEMBL13007161 | 0.93 | PDE9A (0.39) | PDE9AABL1BCRSLC2A1SLC2A2 | |
| SCHEMBL14206876 | 0.86 | PDE9A (0.41) | PDE9AABL1BCRSLC2A1SLC2A2 | |
| SCHEMBL2077088 | 0.86 | ABL1 (0.39) | PDE9AABL1BCRSLC2A1SLC2A2 | |
| SCHEMBL2077112 | 0.85 | ABL1 (0.38) | PDE9AABL1BCRSLC2A1SLC2A2 | |
| SCHEMBL2076325 | 0.85 | PDE9A (0.45) | PDE9ALMNATP53MAPTGRM1 | |
| SCHEMBL2303691 | 0.84 | PDE9A (0.43) | PDE9AABL1BCRSLC2A1SLC2A2 | |
| SCHEMBL2075109 | 0.84 | CHEK1 (0.47) | PDE9AABL1BCRSLC2A1SLC2A2 | |
| SCHEMBL2078497 | 0.83 | PDE9A (0.48) | PDE9AABL1BCRSLC2A1SLC2A2 | |
| SCHEMBL2075444 | 0.83 | CHEK1 (0.48) | PDE9AABL1BCRSLC2A1SLC2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851468-B2 | Substituted pyrazolo[3,4-d]pyrimidines | CEPHALON, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-20070281949-A1 | Substituted pyrazolopyrimidines | CEPHALON, INC. (US) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281949-A1 | Substituted pyrazolopyrimidines | DPYD, P2RX5, P2RX6 | PDE9A 1977/4885ABL1 2258/4885BCR 3103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.